Status:

COMPLETED

A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Lead Sponsor:

Repros Therapeutics Inc.

Conditions:

Uterine Fibroids

Eligibility:

FEMALE

18-47 years

Phase:

PHASE2

Brief Summary

The primary objective of this study is to determine the safety and efficacy of two oral doses of Proellex administered for up to 2 courses of treatment (18 weeks each), each separated by an Off-Drug I...

Eligibility Criteria

Inclusion

  • Is a pre-menopausal female, between 18 and 47 years
  • Participant has a history of at least 3 regular menstrual cycles in which menorrhagia (heavy bleeding) is due to uterine fibroids
  • Confirmed uterine fibroid(s) at screening
  • Visit 1 historical pictorial blood loss assessment chart of \>120 milliliters (mL) of blood loss, to ensure participants have a menstrual blood loss of at least 80 mL by Alkaline Hematin Assay (during the baseline assessment period).
  • A Body Mass Index (BMI) between 18 and 45 inclusive

Exclusion

  • Participant is pregnant or lactating or is attempting or expecting to become pregnant during the entire study period
  • Received an investigational drug in the 30 days prior to the screening for this study
  • Has an intrauterine device in place
  • Observation or history of abnormal endometrial biopsy including the presence of endometrial intraepithelial neoplasia
  • Participants with abnormally high liver enzymes or liver disease

Key Trial Info

Start Date :

March 16 2015

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 2 2017

Estimated Enrollment :

43 Patients enrolled

Trial Details

Trial ID

NCT02301897

Start Date

March 16 2015

End Date

June 2 2017

Last Update

June 19 2019

Active Locations (16)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (16 locations)

1

Alabama Clinical Therapeutics, LLC

Birmingham, Alabama, United States, 35235

2

Phoenix, Arizona, United States, 85015

3

MomDoc Women's Health Research

Scottsdale, Arizona, United States, 85251

4

KO Clinical Research, LLC

Fort Lauderdale, Florida, United States, 33316

A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids | DecenTrialz